| 초록 |
Drug-eluting stents (DES) are coronary stents placed into narrowed, diseased coronary arteries that slowly releases a drug to block cell proliferation. They had developed by the cardiovascular device companies, Boston Scientific and Johnson&Johnson, who market the leading devices Taxus and Cypher. In contrast, drug-eluting non-vascular stents have not been extensively studied and not launched yet. In this work, synthetic hydrogel copolymers with hydrophilic and hydrophobic parts were applied to drug carrier vehicles. And a hydrophobic docetaxel was used as an anticancer agent. Characterization, swelling behavior, surface analysis, and in vitro drug release for the above drug-eluting system were evaluated according to hydrogel and drug contents. |
